Alternatives to Breztri Aerosphere If You Can't Fill Your Prescription

Going without your maintenance COPD inhaler is never a good option. Breztri Aerosphere is a triple-combination inhaler — combining budesonide (ICS), glycopyrrolate (LAMA), and formoterol fumarate (LABA) — that works hard to prevent COPD flare-ups and improve daily breathing. But if your pharmacy doesn't have it in stock, your insurance won't cover it, or cost is the barrier, you need a backup plan fast. This guide covers the best Breztri alternatives and how to approach your doctor about making a switch.

Important: Never switch COPD inhalers on your own. Always talk to your doctor or pulmonologist before starting or stopping any maintenance inhaler. The wrong substitution can trigger dangerous flare-ups.

What Makes Breztri Different From Other Inhalers?

Breztri is one of only two FDA-approved fixed-dose triple-combination inhalers available in the United States (the other being Trelegy Ellipta). Triple therapy — combining an ICS, LAMA, and LABA in one device — is considered the most comprehensive maintenance approach for COPD patients who have moderate-to-severe disease or a history of frequent exacerbations. In the ETHOS trial, Breztri reduced the annual rate of moderate-to-severe exacerbations by 24% compared to LAMA/LABA therapy alone.

Best Alternative #1: Trelegy Ellipta (Fluticasone/Umeclidinium/Vilanterol)

Trelegy Ellipta is the closest like-for-like alternative to Breztri Aerosphere. It is also an ICS/LAMA/LABA triple-combination inhaler, FDA-approved for COPD maintenance, and also approved for asthma. The key differences:

Active ingredients: Trelegy contains fluticasone furoate (ICS), umeclidinium (LAMA), and vilanterol (LABA) — different from Breztri's budesonide, glycopyrrolate, and formoterol.

Dosing: Trelegy is taken once daily (one inhalation), compared to Breztri's twice daily (two puffs, twice a day). Once-daily dosing may improve adherence.

Device: Trelegy uses a dry powder inhaler (Ellipta device), while Breztri uses a pressurized metered-dose inhaler (MDI). Some patients find the Ellipta easier to use.

Price: Cash prices are comparable, typically $550–$700 per month. Insurance coverage varies by plan.

Best Alternative #2: Symbicort (Budesonide/Formoterol) — With or Without Generic

Symbicort is a dual-combination ICS/LABA inhaler containing budesonide and formoterol — two of the three ingredients in Breztri. A generic version of Symbicort (budesonide/formoterol) is available, making it significantly more affordable (often $50–$150 per month). Symbicort is approved for both COPD and asthma. The limitation: it lacks a LAMA component (glycopyrrolate in Breztri's case), so it may not provide the same level of bronchodilation as triple therapy. Your doctor may pair it with a separate LAMA inhaler like tiotropium (Spiriva) to approximate triple therapy at a lower cost.

Best Alternative #3: Two-Inhaler Triple Therapy Combinations

If a single triple-therapy inhaler is unavailable or unaffordable, your doctor can replicate triple therapy using two separate inhalers. Common combinations include:

Generic Symbicort (ICS/LABA) + Spiriva Respimat or HandiHaler (LAMA tiotropium)

Breo Ellipta (ICS/LABA fluticasone/vilanterol) + Incruse Ellipta (LAMA umeclidinium)

Generic Advair (ICS/LABA) + a LAMA inhaler

This approach delivers the same three classes of medications as Breztri but requires managing two devices. For patients concerned about cost, generic ICS/LABA options are much more affordable than any brand-name triple-therapy inhaler.

Best Alternative #4: Anoro Ellipta (Umeclidinium/Vilanterol) — LAMA/LABA Only

For patients who need to reduce or eliminate their corticosteroid component (for example, due to recurrent pneumonia), Anoro Ellipta is a once-daily dual LAMA/LABA inhaler. It bronchodilates through two complementary pathways but has no ICS. This is a significant step down from triple therapy, so it should only be considered under direct medical supervision and for patients where the risks of ICS outweigh the benefits.

How to Talk to Your Doctor About Switching Inhalers

When calling your doctor's office, be specific:

Tell them you can't fill Breztri (state whether it's a stock issue or a cost/insurance issue).

Ask about Trelegy Ellipta as a first alternative — it may be covered differently on your plan.

Mention generic Symbicort if cost is the issue — it dramatically reduces monthly spending.

Ask how long you may need to stay on the alternative and what criteria to return to Breztri.

Before You Switch: Try Harder to Find Breztri

Before you make a switch, exhaust your options for finding Breztri first. Read our guide on how to find Breztri in stock near you for strategies including mail-order, independent pharmacies, and AstraZeneca's Zero Pay program. Sometimes Breztri is available — you just need to know where to look.

The Bottom Line

If you truly can't get Breztri Aerosphere filled, effective alternatives exist. Trelegy Ellipta offers the closest like-for-like triple therapy, while generic Symbicort plus a separate LAMA inhaler provides more affordable coverage. Work closely with your prescriber to find the right bridge therapy, and use medfinder to exhaust all in-stock options before switching.